---
schema_version: "secwatch.filing_event.v1"
accession: "0001549595-24-000138"
form_type: "8-K"
ticker: "NRIX"
cik: "0001549595"
company_name: "Nurix Therapeutics, Inc."
filed_at: "2024-10-16T23:59:59+00:00"
generated_at: "2026-05-30T13:41:03.632480+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Nurix appoints drug commercialization veteran Anil Kapur to board of directors

## Summary
- Appointed Anil Kapur as Class I director effective Oct 15, 2024, with term expiring at 2027 annual meeting.
- Mr. Kapur brings 25+ years of pharma exec experience, including launching Imbruvica and Darzalex.
- Received initial stock option for 50,000 shares vesting monthly over 3 years, plus annual equity awards.
- Appointment aims to support plan to advance NX-5948 into pivotal testing in 2025 and prepare for commercialization.

## SEC filing metadata
- accession: 0001549595-24-000138
- form_type: 8-K
- ticker: NRIX
- cik: 0001549595
- company_name: Nurix Therapeutics, Inc.
- filed_at: 2024-10-16T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549595/000154959524000138/0001549595-24-000138-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549595/000154959524000138/nrix-20241015.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549595-24-000138
- JSON: https://secwatch.observer/filing/0001549595-24-000138.json
- Plain text: https://secwatch.observer/filing/0001549595-24-000138.txt

## Key facts
- Executive change
  Anil Kapur was appointed as Director at Nurix Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: On October 15, 2024, the board of directors (the “Board”) of Nurix Therapeutics, Inc. (the “Company”), following a recommendation from the Nominating and Corporate Governance Committee of the Board, appointed Anil Kapur to serve as a director of the Company and as a member of the Development Advisory Committee of the Board (the “Development Advisory Committee”), effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1549595/000154959524000138/0001549595-24-000138-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.